Spritam
Myoclonic Epilepsy, Juvenile, myoclonic seizures, Seizures + 4 more
Treatment
2 FDA approvals
5 Active Studies for Spritam
Treatment for
Myoclonic Epilepsy, Juvenile
What is Spritam
Levetiracetam
The Generic name of this drug
Treatment Summary
Levetiracetam is an anti-seizure medication used to treat epilepsy and other seizure disorders. It was approved for use in the US in 1999 and is different from other anti-epileptic drugs. Levetiracetam has a wide range of effectiveness and does not interact with other drugs, making it a preferred choice over other anti-epileptic drugs.
Keppra
is the brand name
Spritam Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Keppra
Levetiracetam
2000
604
Approved as Treatment by the FDA
Levetiracetam, otherwise known as Keppra, is approved by the FDA for 2 uses like Partial-Onset Seizures and Seizures .
Partial-Onset Seizures
Seizures
Effectiveness
How Spritam Affects Patients
Levetiracetam works to stop seizures, though it is not clear exactly how it does this. It is considered to be a relatively safe drug compared to other anti-epileptic medications. However, taking levetiracetam may increase the risk of suicidal thoughts or behaviours, so patients should be monitored for any signs of depression, suicidal thoughts, or odd behaviours.
How Spritam works in the body
We don't know exactly how levetiracetam works to treat epilepsy but it appears to bind to a protein called synaptic vesicle protein 2A (SV2A). This protein helps move neurotransmitters from inside the cell to outside the cell. Levetiracetam stimulates SV2A which may inhibit the release of neurotransmitters, but it only does this when there is a pathophysiological condition. It also affects GABAergic neurotransmission and calcium channels, though it is unclear how these actions help treat epilepsy.
When to interrupt dosage
The measure of Spritam is contingent upon the diagnosed affliction, including Seizures, Juvenile myoclonic epilepsy and Epilepsies. The dosage fluctuates depending on the method of delivery (e.g. Tablet, for suspension or Intravascular) featured in the table beneath.
Condition
Dosage
Administration
Disease
, 100.0 mg/mL, 500.0 mg, 750.0 mg, 1000.0 mg, 250.0 mg, 1500.0 mg, 500.0 mg/mL, 5.0 mg/mL, 10.0 mg/mL, 15.0 mg/mL, 150.0 mg/mL
Solution, Solution - Oral, Oral, , Tablet, film coated - Oral, Tablet, film coated, Intravenous, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, Injection, solution - Intravenous, Injection, solution, Tablet, for suspension, Tablet, for suspension - Oral, Tablet, Chewable, Extended Release - Oral, Tablet, Chewable, Extended Release, Solution - Intravenous, Aerosol - Oral, Injection - Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection - Intravascular, Intravascular, Aerosol
myoclonic seizures
, 100.0 mg/mL, 500.0 mg, 750.0 mg, 1000.0 mg, 250.0 mg, 1500.0 mg, 500.0 mg/mL, 5.0 mg/mL, 10.0 mg/mL, 15.0 mg/mL, 150.0 mg/mL
Solution, Solution - Oral, Oral, , Tablet, film coated - Oral, Tablet, film coated, Intravenous, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, Injection, solution - Intravenous, Injection, solution, Tablet, for suspension, Tablet, for suspension - Oral, Tablet, Chewable, Extended Release - Oral, Tablet, Chewable, Extended Release, Solution - Intravenous, Aerosol - Oral, Injection - Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection - Intravascular, Intravascular, Aerosol
Seizures
, 100.0 mg/mL, 500.0 mg, 750.0 mg, 1000.0 mg, 250.0 mg, 1500.0 mg, 500.0 mg/mL, 5.0 mg/mL, 10.0 mg/mL, 15.0 mg/mL, 150.0 mg/mL
Solution, Solution - Oral, Oral, , Tablet, film coated - Oral, Tablet, film coated, Intravenous, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, Injection, solution - Intravenous, Injection, solution, Tablet, for suspension, Tablet, for suspension - Oral, Tablet, Chewable, Extended Release - Oral, Tablet, Chewable, Extended Release, Solution - Intravenous, Aerosol - Oral, Injection - Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection - Intravascular, Intravascular, Aerosol
Epilepsy
, 100.0 mg/mL, 500.0 mg, 750.0 mg, 1000.0 mg, 250.0 mg, 1500.0 mg, 500.0 mg/mL, 5.0 mg/mL, 10.0 mg/mL, 15.0 mg/mL, 150.0 mg/mL
Solution, Solution - Oral, Oral, , Tablet, film coated - Oral, Tablet, film coated, Intravenous, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, Injection, solution - Intravenous, Injection, solution, Tablet, for suspension, Tablet, for suspension - Oral, Tablet, Chewable, Extended Release - Oral, Tablet, Chewable, Extended Release, Solution - Intravenous, Aerosol - Oral, Injection - Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection - Intravascular, Intravascular, Aerosol
Epilepsy, Generalized
, 100.0 mg/mL, 500.0 mg, 750.0 mg, 1000.0 mg, 250.0 mg, 1500.0 mg, 500.0 mg/mL, 5.0 mg/mL, 10.0 mg/mL, 15.0 mg/mL, 150.0 mg/mL
Solution, Solution - Oral, Oral, , Tablet, film coated - Oral, Tablet, film coated, Intravenous, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, Injection, solution - Intravenous, Injection, solution, Tablet, for suspension, Tablet, for suspension - Oral, Tablet, Chewable, Extended Release - Oral, Tablet, Chewable, Extended Release, Solution - Intravenous, Aerosol - Oral, Injection - Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection - Intravascular, Intravascular, Aerosol
Obesity
, 100.0 mg/mL, 500.0 mg, 750.0 mg, 1000.0 mg, 250.0 mg, 1500.0 mg, 500.0 mg/mL, 5.0 mg/mL, 10.0 mg/mL, 15.0 mg/mL, 150.0 mg/mL
Solution, Solution - Oral, Oral, , Tablet, film coated - Oral, Tablet, film coated, Intravenous, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, Injection, solution - Intravenous, Injection, solution, Tablet, for suspension, Tablet, for suspension - Oral, Tablet, Chewable, Extended Release - Oral, Tablet, Chewable, Extended Release, Solution - Intravenous, Aerosol - Oral, Injection - Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection - Intravascular, Intravascular, Aerosol
Myoclonic Epilepsy, Juvenile
, 100.0 mg/mL, 500.0 mg, 750.0 mg, 1000.0 mg, 250.0 mg, 1500.0 mg, 500.0 mg/mL, 5.0 mg/mL, 10.0 mg/mL, 15.0 mg/mL, 150.0 mg/mL
Solution, Solution - Oral, Oral, , Tablet, film coated - Oral, Tablet, film coated, Intravenous, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, Injection, solution - Intravenous, Injection, solution, Tablet, for suspension, Tablet, for suspension - Oral, Tablet, Chewable, Extended Release - Oral, Tablet, Chewable, Extended Release, Solution - Intravenous, Aerosol - Oral, Injection - Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection - Intravascular, Intravascular, Aerosol
Warnings
Spritam Contraindications
Condition
Risk Level
Notes
Severe Hypersensitivity Reactions
Do Not Combine
Levetiracetam may interact with Pulse Frequency
There are 20 known major drug interactions with Spritam.
Common Spritam Drug Interactions
Drug Name
Risk Level
Description
Azelastine
Major
Levetiracetam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Ethanol
Major
Levetiracetam may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Oliceridine
Major
The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Levetiracetam is combined with Oliceridine.
Thalidomide
Major
Levetiracetam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Daridorexant
Minor
The risk or severity of CNS depression can be increased when Levetiracetam is combined with Daridorexant.
Spritam Toxicity & Overdose Risk
The lowest toxic dose of levetiracetam in humans is 10mg/kg. Signs of an overdose may include restlessness, aggression, sleepiness, decreased consciousness, shallow breathing, or a coma. There is no specific antidote for overdose, so treatments should focus on supporting the patient and managing their symptoms. Dialysis can be used to reduce the amount of drug in the bloodstream by up to 50% within 4 hours.
Spritam Novel Uses: Which Conditions Have a Clinical Trial Featuring Spritam?
At present, 3 active studies are assessing the potential of Spritam to reduce myoclonic seizures, Juvenile myoclonic epilepsy and Idiopathic Generalized Epilepsy.
Condition
Clinical Trials
Trial Phases
Epilepsy
0 Actively Recruiting
Seizures
5 Actively Recruiting
Phase 3, Phase 2, Phase 1
Epilepsy, Generalized
0 Actively Recruiting
myoclonic seizures
0 Actively Recruiting
Myoclonic Epilepsy, Juvenile
0 Actively Recruiting
Disease
0 Actively Recruiting
Obesity
0 Actively Recruiting
Spritam Reviews: What are patients saying about Spritam?
3
Patient Review
8/1/2017
Spritam for Additional Medication to Treat Partial Seizures
Patient Q&A Section about spritam
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
What is Spritam used for?
"Spritam is a medication used to treat seizures in both children and adults. It is effective against many types of seizures, including partial-onset, myoclonic, and tonic-clonic seizures. Spritam is available as a tablet that easily dissolves in your mouth."
Answered by AI
How does Xcopri work?
"This medication is used to treat partial onset seizure disorder. Its exact mechanism is unknown, but it might work by affecting some nerves that are linked to seizures."
Answered by AI
What should you not take with Keppra?
"Some common medications that may interact with Keppra are antidepressants, antiepileptics, and benzodiazepines."
Answered by AI
Who makes SPRITAM?
"You may report any side effects you experience to Aprecia Pharmaceuticals, LLC by calling 1-844-882-7732 or to the FDA by calling 1-800-FDA-1088. SPRITAM (levetiracetam) is an antiepileptic drug available as 250 mg, 500 mg, 750 mg, and 1000 mg round, white to off-white, spearmint-flavored tablets for oral suspension."
Answered by AI